Ruben J. Colman, MD
- Advanced Fellow in IBD, Division of Gastroenterology, Hepatology and Nutrition
About
Biography
Ruben J. Colman, MD, FAAP, is a clinical fellow in the division of Gastroenterology, Hepatology and Nutrition. As a fellow in pediatric gastroenterology, his clinical training focuses on the care of a wide variety of pediatric gastrointestinal and liver diseases. Dr. Colman’s medical and clinical training in the Netherlands, Chicago, New York City, and Cincinnati prepared him to care for patients from all backgrounds and with a range of complex gastrointestinal conditions. His primary clinical interests include complex conditions, particularly pediatric inflammatory bowel diseases, which require interdisciplinary, collaborative, and innovative care.
Dr. Colman’s research focuses on improving clinical care for pediatric patients with inflammatory bowel diseases (IBD). In an effort to implement personalized medicine in IBD care, he uses precision medicine to best predict optimal treatment pathways for pediatric IBD patients. This reflects a broader goal to prevent disease progression and complications, utilizing precision medicine approaches focusing on clinical pharmacology and gut microbiome interactions.
He will serve on the research committee of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).
MSc: University of Amsterdam, Amsterdam, The Netherlands, 2010.
MD: University of Amsterdam, Amsterdam, The Netherlands, 2012.
Residency: Pediatrics, SBH Health System, the Bronx, NY, 2018.
Certification: Pediatrics, 2018.
Interests
Pediatric gastroenterology; inflammatory bowel disease (IBD); fecal microbiota transplantation (FMT)
Services and Specialties
Gastroenterology GI
Interests
Inflammatory bowel diseases; clinical pharmacology; microbiome; pharmacomicrobiomics; precision medicine
Publications
Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease. Alimentary Pharmacology and Therapeutics. 2022; 55:593-603.
Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease. Inflammatory Bowel Diseases. 2021; 27:1045-1051.
Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Clinical Pharmacology and Therapeutics. 2021; 109:1639-1647.
Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients. Inflammatory Bowel Diseases. 2021; 27:507-515.
Predicting Therapeutic Response in Pediatric Ulcerative Colitis-A Journey Towards Precision Medicine. Frontiers in Pediatrics. 2021; 9:634739.
Upper GI Endoscopy in Adolescents with Severe Obesity Prior to Vertical Sleeve Gastrectomy. Journal of Pediatric Gastroenterology and Nutrition. 2019; 69:287-291.
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology. 2019; 17:486-493.
Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases. 2018; 24:2135-2141.
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflammatory Bowel Diseases. 2018; 24:849-860.
Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease. Journal of Crohn's and Colitis. 2015; 9:312-317.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
